John J Chen1, Eoin P Flanagan2, Jiraporn Jitprapaikulsan3, Alfonso Sebastian S López-Chiriboga4, James P Fryer5, Jacqueline A Leavitt6, Brian G Weinshenker7, Andrew McKeon2, Jan-Mendelt Tillema4, Vanda A Lennon8, W Oliver Tobin7, B Mark Keegan7, Claudia F Lucchinetti7, Orhun H Kantarci7, Collin M McClelland9, Michael S Lee9, Jeffrey L Bennett10, Victoria S Pelak10, Yanjun Chen11, Gregory VanStavern12, Ore-Ofe O Adesina13, Eric R Eggenberger14, Marie D Acierno15, Dean M Wingerchuk16, Paul W Brazis14, Jessica Sagen17, Sean J Pittock2. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Chen.john@mayo.edu. 2. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA; Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 6. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA. 7. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA. 8. Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA; Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA; Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA. 9. Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA. 10. Departments of Neurology and Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA. 11. Department of Ophthalmology, Neurology and Neurosurgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 12. Departments of Ophthalmology and Visual Sciences and Neurology, Washington University, St. Louis School of Medicine, St. Louis, Missouri, USA. 13. Departments of Ophthalmology and Visual Science and Neurology, McGovern Medical School, Houston, Texas, USA. 14. Departments of Neurology and Neuro-Ophthalmology Mayo Clinic, Jacksonville, Florida, USA. 15. Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona, USA. 16. Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA. 17. Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE: To characterize the clinical phenotype of myelin oligodendrocyte glycoprotein antibody (MOG-IgG) optic neuritis. DESIGN: Observational case series. METHODS: Setting: Multicenter. Patient/Study Population: Subjects meeting inclusion criteria: (1) history of optic neuritis; (2) seropositivity (MOG-IgG binding index > 2.5); 87 MOG-IgG-seropositive patients with optic neuritis were included (Mayo Clinic, 76; other medical centers, 11). MOG-IgG was detected using full-length MOG-transfected live HEK293 cells in a clinically validated flow cytometry assay. MAIN OUTCOME MEASURES: Clinical and radiologic characteristics and visual outcomes. RESULTS: Fifty-seven percent were female and median age at onset was 31 (range 2-79) years. Median number of optic neuritis attacks was 3 (range 1-8), median follow-up 2.9 years (range 0.5-24 years), and annualized relapse rate 0.8. Average visual acuity (VA) at nadir of worst attack was count fingers. Average final VA was 20/30; for 5 patients (6%) it was ≤20/200 in either eye. Optic disc edema and pain each occurred in 86% of patients. Magnetic resonance imaging showed perineural enhancement in 50% and longitudinally extensive involvement in 80%. Twenty-six patients (30%) had recurrent optic neuritis without other neurologic symptoms, 10 (12%) had single optic neuritis, 14 (16%) had chronic relapsing inflammatory optic neuropathy, and 36 (41%) had optic neuritis with other neurologic symptoms (most neuromyelitis optica spectrum disorder-like phenotype or acute disseminated encephalomyelitis). Only 1 patient was diagnosed with MS (MOG-IgG-binding index 2.8; normal range ≤ 2.5). Persistent MOG-IgG seropositivity occurred in 61 of 62 (98%). A total of 61% received long-term immunosuppressant therapy. CONCLUSIONS: Manifestations of MOG-IgG-positive optic neuritis are diverse. Despite recurrent attacks with severe vision loss, the majority of patients have significant recovery and retain functional vision long-term.
PURPOSE: To characterize the clinical phenotype of myelin oligodendrocyte glycoprotein antibody (MOG-IgG) optic neuritis. DESIGN: Observational case series. METHODS: Setting: Multicenter. Patient/Study Population: Subjects meeting inclusion criteria: (1) history of optic neuritis; (2) seropositivity (MOG-IgG binding index > 2.5); 87 MOG-IgG-seropositive patients with optic neuritis were included (Mayo Clinic, 76; other medical centers, 11). MOG-IgG was detected using full-length MOG-transfected live HEK293 cells in a clinically validated flow cytometry assay. MAIN OUTCOME MEASURES: Clinical and radiologic characteristics and visual outcomes. RESULTS: Fifty-seven percent were female and median age at onset was 31 (range 2-79) years. Median number of optic neuritis attacks was 3 (range 1-8), median follow-up 2.9 years (range 0.5-24 years), and annualized relapse rate 0.8. Average visual acuity (VA) at nadir of worst attack was count fingers. Average final VA was 20/30; for 5 patients (6%) it was ≤20/200 in either eye. Optic disc edema and pain each occurred in 86% of patients. Magnetic resonance imaging showed perineural enhancement in 50% and longitudinally extensive involvement in 80%. Twenty-six patients (30%) had recurrent optic neuritis without other neurologic symptoms, 10 (12%) had single optic neuritis, 14 (16%) had chronic relapsing inflammatory optic neuropathy, and 36 (41%) had optic neuritis with other neurologic symptoms (most neuromyelitis optica spectrum disorder-like phenotype or acute disseminated encephalomyelitis). Only 1 patient was diagnosed with MS (MOG-IgG-binding index 2.8; normal range ≤ 2.5). Persistent MOG-IgG seropositivity occurred in 61 of 62 (98%). A total of 61% received long-term immunosuppressant therapy. CONCLUSIONS: Manifestations of MOG-IgG-positive optic neuritis are diverse. Despite recurrent attacks with severe vision loss, the majority of patients have significant recovery and retain functional vision long-term.
Authors: B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez Journal: Ann Neurol Date: 1999-12 Impact factor: 10.422
Authors: John J Chen; W Oliver Tobin; Masoud Majed; Jiraporn Jitprapaikulsan; James P Fryer; Jacqueline A Leavitt; Eoin P Flanagan; Andrew McKeon; Sean J Pittock Journal: JAMA Ophthalmol Date: 2018-04-01 Impact factor: 7.389
Authors: Patrick Waters; Mark Woodhall; Kevin C O'Connor; Markus Reindl; Bethan Lang; Douglas K Sato; Maciej Juryńczyk; George Tackley; Joao Rocha; Toshiyuki Takahashi; Tatsuro Misu; Ichiro Nakashima; Jacqueline Palace; Kazuo Fujihara; M Isabel Leite; Angela Vincent Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-03-19
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910
Authors: Konstantina Chalmoukou; Harry Alexopoulos; Sofia Akrivou; Panos Stathopoulos; Markus Reindl; Marinos C Dalakas Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-07-02
Authors: Florence Pache; Hanna Zimmermann; Janine Mikolajczak; Sophie Schumacher; Anna Lacheta; Frederike C Oertel; Judith Bellmann-Strobl; Sven Jarius; Brigitte Wildemann; Markus Reindl; Amy Waldman; Kerstin Soelberg; Nasrin Asgari; Marius Ringelstein; Orhan Aktas; Nikolai Gross; Mathias Buttmann; Thomas Ach; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt Journal: J Neuroinflammation Date: 2016-11-01 Impact factor: 8.322
Authors: Elias S Sotirchos; Angeliki Filippatou; Kathryn C Fitzgerald; Sara Salama; Santiago Pardo; Jiangxia Wang; Esther Ogbuokiri; Norah J Cowley; Nicole Pellegrini; Olwen C Murphy; Maureen A Mealy; Jerry L Prince; Michael Levy; Peter A Calabresi; Shiv Saidha Journal: Mult Scler Date: 2019-07-31 Impact factor: 6.312
Authors: A Sebastian Lopez-Chiriboga; Gregory Van Stavern; Eoin P Flanagan; Sean J Pittock; Jim Fryer; M Tariq Bhatti; John J Chen Journal: Neuroophthalmology Date: 2019-05-28
Authors: Soren Jonzzon; Leena Suleiman; Andrew Yousef; Brenda Young; Janace Hart; Patrick Peschl; Markus Reindl; Kristin L Schaller; Jeffrey L Bennett; Emmanuelle Waubant; Jennifer S Graves Journal: J Child Neurol Date: 2019-09-30 Impact factor: 1.987